| Dexamethasone in hospitalized patients with Covid-19 RECOVERY Collaborative Group New England Journal of Medicine 384 (8), 693-704, 2021 | 3001 | 2021 |
| Effect of hydroxychloroquine in hospitalized patients with Covid-19 RECOVERY Collaborative Group New England Journal of Medicine 383 (21), 2030-2040, 2020 | 1550 | 2020 |
| Empagliflozin in patients with chronic kidney disease EMPA-Kidney Collaborative Group New England Journal of Medicine 388 (2), 117-127, 2023 | 1521 | 2023 |
| Effects of Aspirin for Primary Prevention in Persons with Diabetes Mellitus ASCEND Study Collaborative Group New England Journal of Medicine, 2018 | 1262 | 2018 |
| Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial RECOVERY Collaborative Group Lancet (London, England) 397 (10285), 1637, 2021 | 1235 | 2021 |
| Effects of anacetrapib in patients with atherosclerotic vascular disease HPS3/TIMI55–REVEAL Collaborative Group New England Journal of Medicine 377 (13), 1217-1227, 2017 | 1002 | 2017 |
| Effects of n− 3 Fatty Acid Supplements in Diabetes Mellitus ASCEND Study Collaborative Group New England Journal of Medicine, 2018 | 802 | 2018 |
| Lithium plus valproate combination therapy versus monotherapy for relapse prevention in bipolar I disorder (BALANCE): a randomised open-label trial. S Lewis, JR Geddes, G Goodwin, R Morriss, J Rendell, MJ Attenburrow, ... Lancet 375 (9712), 385-95, 2010 | 614 | 2010 |
| Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial RECOVERY Collaborative Group Lancet (London, England) 397 (10289), 2049, 2021 | 334 | 2021 |
| Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial RECOVERY Collaborative Group Lancet (London, England) 397 (10274), 605, 2021 | 233 | 2021 |
| Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial RECOVERY Collaborative Group Lancet (London, England) 399 (10325), 665, 2022 | 231 | 2022 |
| Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial RECOVERY Collaborative Group Lancet (London, England) 399 (10320), 143, 2022 | 214 | 2022 |
| The longitudinal course of bipolar disorder as revealed through weekly text messaging: a feasibility study JM Bopp, DJ Miklowitz, GM Goodwin, W Stevens, JM Rendell, JR Geddes Bipolar disorders 12 (3), 327-334, 2010 | 213 | 2010 |
| Colchicine in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial RECOVERY Collaborative Group The Lancet Respiratory Medicine 9 (12), 1419-1426, 2021 | 158 | 2021 |
| ASCEND: A Study of Cardiovascular Events iN Diabetes: Characteristics of a randomized trial of aspirin and of omega-3 fatty acid supplementation in 15,480 people with diabetes JA Louise Bowman,Marion Mafham,William Stevens,Richard Haynes,Theingi Aung ... American Heart Journal, 2017 | 135* | 2017 |
| Design, recruitment, and baseline characteristics of the EMPA-KIDNEY trial Nephrology Dialysis Transplantation 37 (7), 1317-1329, 2022 | 103 | 2022 |
| Randomized Evaluation of the Effects of Anacetrapib through Lipid-modification (REVEAL)—A large-scale, randomized, placebo-controlled trial of the clinical effects of … MJ Landray, L Bowman, F Chen, E Sammons, JC Hopewell, ... American heart journal 187, 182-190, 2017 | 67 | 2017 |
| Impact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: secondary analyses of the EMPA-KIDNEY trial PK Judge, N Staplin, KJ Mayne, C Wanner, JB Green, SJ Hauske, ... The Lancet Diabetes & Endocrinology 12 (1), 51-60, 2024 | 50 | 2024 |
| The True Colours Remote Symptom Monitoring System: A Decade of Evolution SM Goodday, L Atkinson, G Goodwin, K Saunders, M South, C Mackay, ... Journal of Medical Internet Research 22 (1), e15188, 2020 | 47 | 2020 |
| Effects of empagliflozin on progression of chronic kidney disease: a prespecified secondary analysis from the EMPA-KIDNEY trial N Staplin, R Haynes, PK Judge, C Wanner, JB Green, J Emberson, ... The Lancet Diabetes & Endocrinology, 2023 | 46 | 2023 |
